Stocks to Watch: Elan, Theravance, Take-Two

NEW YORK -- Elan ( ELN) and Theravance ( THRX) reached a $1 billion agreement in which Elan will buy 21% of royalties that Theravance receives from GlaxoSmithKline ( GSK) for four respiratory drugs.

The deal includes Breo Ellipta, a new treatment for chronic obstructive pulmonary disease that received approval from the Food and Drug Administration last week.

4 Stocks Spiking on Big Volume


Take-Two Interactive Software ( TTWO) is expected by analysts on Monday to post fiscal fourth-quarter earnings of 23 cents a share on revenue of $280.1 million.


Cereal company Post Holdings ( POST) is expected by Wall Street to report fiscal second-quarter earnings of 27 cents a share on revenue of $255.7 million.


Ann Inc. ( ANN) is forecast to post first-quarter earnings of 43 cents a share on sales of $582 million.


Pacific Sunwear ( PSUN) is expected by analysts on Monday to post a first-quarter loss of 19 cents a share.

5 Stocks Poised to Break Out


-- Written by Joseph Woelfel

>To contact the writer of this article, click here: Joseph Woelfel

>To submit a news tip, send an email to: tips@thestreet.com.

If you liked this article you might like

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

With Martin Shkreli Long Gone, Retrophin is an 'Interesting Opportunity'

Despite Shkreli Drama, Retrophin Looks Interesting Now

Celtic Tiger Tries to Roar Again

Cramer's 6 Stocks in 60 Seconds: PRGO CREE HOG GME ORCL MHK (Update 1)